Gilead Sciences, Inc. (TSX:GILD)

Market Cap	249.81B +45.7%
Revenue (ttm)	40.37B +2.4%
Net Income	11.67B +1,672.9%
EPS	9.30 +1,684.2%
Shares Out	n/a
PE Ratio	21.41
Forward PE	16.86
Dividend	0.49 (1.63%)
Ex-Dividend Date	Dec 15, 2025

Volume	7,468
Average Volume	3,248
Open	29.80
Previous Close	29.98
Day's Range	29.37 - 29.80
52-Week Range	20.08 - 31.80
Beta	n/a
RSI	48.65
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.

Financial numbers in USD